Language:English
Language:

Xcessbio

Place your promotion here

You have no items in your shopping cart.

BAF312, S1P1/5 Selective Agonist

BAF312, S1P1/5 Selective Agonist

$129.00
A potent and selective sphingosine 1-phosphate (S1P1/5) receptor agonist in clinical trials.
Catalog No. Unit Price Qty
M60039-2s 2 mg solid $129.00
M60039-2 10 mM in DMSO (0.388 mL) $129.00
M60039-50s 50 mg solid $980.00

Details

Product Information
Chemical Name: (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid
Molecular Weight: 516.60
Formula: C29H35F3N2O3
Purity: ≥ 98%
CAS#: 800379-64-0
Solubility: DMSO up to 100 mM
Storage: Powder: 4oC 1 year DMSO: 4oC 3 month -20oC 1 year


Biological Activity:

BAF312 is a next-generation potent sphingosine 1-phosphate (S1P) receptor agonist, selective for S1P1 (EC50 ~0.39 nM) and S1P5 (EC50 ~0.98 nM). As S1P1 plays a central role in lymphocyte egress from lymph nodes and is a validated drug target in immune-mediated diseases, BAF312 is currently in clinical trials to treat multiple sclerosis.


How to Use:

In vitro:  BAF312 was used at 0.1µM in vitro.

In vivo: BAF312 was orally dosed once daily at 0.3-3 mg/kg in chronic EAE, DA rats and was shown good efficacy.


Reference:

  1. 1. Gergely P, et al. The selective S1P receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate: translation from preclinical to clinical studies. (2012) Br J Pharmacol. 167(5):1035-47.
  2. 2. Pan SF, et al. Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator. (2013) ACS Med. Chem. Lett. In press.
  3. 3. Fryer RM, et al. The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat. (2012) PLoS One. (12):e52985.


   BAF312_spec.pdf 

   BAF312_MSDS.pdf


Products are for research use only. Not for human use.

Description

Details

Product Information
Chemical Name: (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid
Molecular Weight: 516.60
Formula: C29H35F3N2O3
Purity: ≥ 98%
CAS#: 800379-64-0
Solubility: DMSO up to 100 mM
Storage: Powder: 4oC 1 year DMSO: 4oC 3 month -20oC 1 year


Biological Activity:

BAF312 is a next-generation potent sphingosine 1-phosphate (S1P) receptor agonist, selective for S1P1 (EC50 ~0.39 nM) and S1P5 (EC50 ~0.98 nM). As S1P1 plays a central role in lymphocyte egress from lymph nodes and is a validated drug target in immune-mediated diseases, BAF312 is currently in clinical trials to treat multiple sclerosis.


How to Use:

In vitro:  BAF312 was used at 0.1µM in vitro.

In vivo: BAF312 was orally dosed once daily at 0.3-3 mg/kg in chronic EAE, DA rats and was shown good efficacy.


Reference:

  1. 1. Gergely P, et al. The selective S1P receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate: translation from preclinical to clinical studies. (2012) Br J Pharmacol. 167(5):1035-47.
  2. 2. Pan SF, et al. Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator. (2013) ACS Med. Chem. Lett. In press.
  3. 3. Fryer RM, et al. The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat. (2012) PLoS One. (12):e52985.


   BAF312_spec.pdf 

   BAF312_MSDS.pdf


Products are for research use only. Not for human use.

Reviews

Write Your Review

How do you rate this product? *

Price:
Value:
Quality: